News
- Author:
- Sara Freeman
Publish date: July 6, 2018
AMSTERDAM – Few clinical and serologic markers predict response to rituximab in patients with systemic lupus eryt...
News
- Author:
- Sara Freeman
Publish date: July 6, 2018
AMSTERDAM – Ultrasound helped visualize the rapid reduction of uric acid load during a treat-to-target approach w...
News
- Author:
- Sara Freeman
Publish date: June 29, 2018
AMSTERDAM – Almost one in five people with rheumatoid arthritis still experience pain 1 year after their diagnosis.
Video
- Author:
- Sara Freeman
Publish date: June 28, 2018
AMSTERDAM – EULAR recommendations provide guidance on the optimal use of glucocorticoids for rheumatoid arthritis and polymyalgia rheumatica.
News
- Author:
- Sara Freeman
Publish date: June 28, 2018
AMSTERDAM – A glucocorticosteroid dose as little as 2 mg/day appears to be an independent risk factor for loss of muscle mass and strength.
News
- Author:
- Sara Freeman
Publish date: June 27, 2018
AMSTERDAM – There were some positive effects of the MRI strategy on several predefined secondary endpoints.
News
- Author:
- Sara Freeman
Publish date: June 27, 2018
AMSTERDAM – Smoking, insufficiently controlled inflammation, and glucocorticoid use were risk factors for heart failure hospitalization and death.<...
News
- Author:
- Sara Freeman
Publish date: June 26, 2018
AMSTERDAM – Worsening OA could be the root of depressive symptoms and surgery is shown to improve depression in R...
Video
- Author:
- Sara Freeman
Publish date: June 22, 2018
AMSTERDAM – New EULAR/ACR criteria for classifying systemic lupus erythematosus had a sensitivity and a specifici...
News
- Author:
- Sara Freeman
Publish date: June 21, 2018
LIVERPOOL, ENGLAND – Serum troponin might prove useful for assessing the risk of cardiovascular mortality in pati...
News
- Author:
- Sara Freeman
Publish date: June 20, 2018
LIVERPOOL, ENGLAND – Work performance was improved with biologic therapy versus without it in an analysis of data...
Video
- Author:
- Sara Freeman
Publish date: June 16, 2018
AMSTERDAM – Although a rare event, there is an increased risk of deliberate self-harm among those newly-diagnosed ankylosing spondylitis.
Video
- Author:
- Sara Freeman
Publish date: June 15, 2018
AMSTERDAM – Positive findings from a phase 2 trial pave the way for further evaluation of baricitinib in systemic...
News
- Author:
- Sara Freeman
Publish date: June 14, 2018
AMSTERDAM – Functional disability has risen over time in patients with RA, with at least a 15% excess, compared w...
News
- Author:
- Sara Freeman
Publish date: June 12, 2018
LIVERPOOL, ENGLAND – Upadacitinib met both of the coprimary endpoints in the trial – ACR 20 response and low disease activity at 12 weeks.
